Every large acquisition comes with a synergy number attached, and H.B. Fuller's $943 million bid for Advanced Medical Solutions (AMS) is no exception. The company has identified approximately $55 million in combined annual run-rate revenue and cost synergies, a figure it expects to fully realize within five years of closing. That number is doing a lot of work in the deal's financial narrative, since it's the primary lever management is pointing to when justifying the acquisition's valuation to skeptical investors.
Where the $55 Million Is Expected to Come From
Synergy estimates tend to sound abstract until they're broken into their component parts. H.B. Fuller has pointed to three specific sources for the projected savings:
Elimination of public company costs, since AMS will no longer need to maintain its own separate listing, board, audit, and regulatory reporting infrastructure once folded into H.B. Fuller.
Rationalization of overlapping expenses, particularly in areas like administrative functions, facilities, and duplicated corporate overhead between the two organizations.
Sourcing savings, achieved by combining procurement volume across raw materials and packaging that feed into both companies' adhesive product lines.
Notably, the synergy figure is described as combined revenue and cost savings rather than cost reduction alone, meaning part of the projected $55 million is expected to come from cross-selling AMS's surgical adhesive and biosurgical products through H.B. Fuller's broader commercial footprint, not just from cutting expenses.
Why the Five-Year Timeline Matters
A five-year runway to full synergy realization is a meaningful detail for anyone evaluating the deal's near-term financial impact. It signals that H.B. Fuller isn't expecting an immediate margin lift from the acquisition. Instead, the benefits will build gradually as integration milestones are completed, systems are consolidated, and cross-selling relationships mature across AMS's pan-European distributor and hospital network.
This matters for how the deal should be evaluated relative to its purchase price. On a pre-synergy basis, H.B. Fuller is paying an EBITDA multiple of roughly 12.9x current AMS earnings. Once the full $55 million in run-rate synergies is achieved, that effective multiple is expected to drop below 8x, a meaningfully more attractive valuation, but one that depends entirely on execution over the coming years rather than being locked in at signing.
Revenue Synergies vs. Cost Synergies: A Different Kind of Bet
It's worth distinguishing between the two types of synergy embedded in that $55 million figure, because they carry different levels of execution risk. Cost synergies, like eliminating duplicate public company expenses, are relatively predictable and tend to materialize on schedule since they're largely within management's direct control. Revenue synergies, by contrast, depend on external factors: whether AMS's hospital and distributor relationships actually convert into new sales for H.B. Fuller's existing product lines, and whether customers respond positively to a combined commercial approach.
Companies that lean more heavily on projected revenue synergies in their deal rationale tend to face more scrutiny from analysts and investors, since those numbers are inherently harder to verify in advance. H.B. Fuller's synergy estimate blends both categories, which is one reason management has framed the figure as a five-year target rather than something achievable immediately post-close.
What This Signals for the Broader Adhesives Market
A $55 million synergy target on a $943 million deal is a modest but not insignificant figure, roughly 5.8% of the purchase price annually once fully realized. For competitors and suppliers in the medical adhesives space, the synergy plan is worth watching for a few reasons:
Sourcing consolidation across the combined entity could shift purchasing volume and negotiating leverage for raw materials shared between H.B. Fuller and AMS's production lines.
Cross-selling ambitions suggest H.B. Fuller intends to actively push AMS's surgical adhesive and biosurgical products into markets and customer relationships it already serves, which could pressure smaller competitors in those categories.
The multi-year timeline gives buyers a rough window for when pricing, product availability, or account structures tied to the merger are most likely to shift.
What Buyers Should Watch as Integration Unfolds
A synergy target is only as good as a company's ability to deliver on it, and H.B. Fuller's five-year timeline gives the market a clear benchmark to measure progress against. Procurement teams working with either company should expect gradual, rather than immediate, changes to sourcing structures and commercial terms as integration proceeds. Tracking how quickly the cost-side synergies materialize relative to the more uncertain revenue-side targets will offer an early read on whether this acquisition is delivering the value H.B. Fuller has promised its shareholders.
Ready to source adhesive raw materials from verified global suppliers? Explore competitive offers on our platform today.
